



Doncaster Place and Bassetlaw Place Medicines Optimisation Bulletin

February 2025



Have you got a spare couple of minutes? Like what you see? Want to hear more from Medicines Optimisation? We need your feedback on the new style bulletin. Use the QR code opposite or follow the link: <https://forms.office.com/e/A21uYN9JJb>

Useful hyperlinks for Medicines Optimisation
To open Press control and click the link below
[IMOC Webpage](#)
[Doncaster Place Website](#)
[MPD](#)

Traffic Light Status (TLS) additions and changes

TLS Integrated medicines Optimisation Committee (IMOC) List approved in February 2025
Please Note: TLS status finalised at IMOC all items are classified as non-Formulary unless stated otherwise. The MPD will be updated accordingly.
For a full list of items that were classified click this link below:
[February 2025 TLS List](#)

New and updated Documents now available on the MO website / MPD

- **New: Melatonin Shared Care Documents** [Click Here](#)
 - For Doncaster :Melatonin in the Management of Sleep Disorders in Children and Young People with Neurodevelopmental Disorders and for adults aged over 18 with a learning disability (off-label)
For Bassetlaw: This Shared Care Guideline ONLY applies for paediatrics patients (under 18 yrs) under the care of DBTHFT and RDASH.
- **Updated :**
 - **ADHD SCP Documents:** Amended to include a new product in the formulary choices [Click Here](#)
 - **Inflammatory Arthritis / Connective Tissue SCP documents:** Replacing the previous documents [Click Here](#)

DIBS Update

You can find latest DIBS Practice information and other useful resources on the DIBS page on the Medicines Management website by clicking this [link](#) If you have any questions around DIBS, please contact the MO team via our email : svyicb-

**For the latest Out of Stock information
Refer to your regular emails from medicines management Admin emails.**

Formulary updates February 2025

The following items were agreed to be added/amended on the MPD

Formulary Section	Item	Indication	PMOC Action
4.7.4.2	Rimegepant - Prevention of migraine	Prevention of migraine	Red Non-formulary
4.7.4.1	Rimegepant - Acute treatment	acute treatment	Green 3rd line
4.7.4.2	Atogepant - Prevention of migraine	Prevention of migraine	Red Non-formulary
1.1.1	Co-magaldrox	Antacid	removed Maalox from choice
1.2	Eluxadoline	Irritable bowel syndrome with diarrhoea (IBS-D) in adults	GREY non-formulary
1.3.1	Famotidine oral	H2 receptor antagonists	Green 1st line formulary for palliative care
1.3.1	Famotidine Injection	H2 receptor antagonists	Famotidine injection Hosp only BLUE palliative care use only replaces ranitidine for palliative care
1.3.1	Ranitidine Injection	H2 receptor antagonists	Ranitidine approved as grey non-formulary for everything as not available

Freestyle Libre Continuous Glucose Monitoring

The first line formulary choice is currently Freestyle Libre 2/ 2 Plus sensor for diabetic patients who fulfil the criteria.

Please Note : Freestyle Libre 3 and 3 plus are only to be prescribed for children with type 1 diabetes and patients using a hybrid closed loop system. There will be a prompt on clinical systems to remind prescribers to check the correct CGM product has been requested.

Contact us : South Yorkshire Integrated Care Board Doncaster Place Medicines Optimisation Team

Phone : 03000 213394

E-mail : svyicb-doncaster.medicinesmanagementadmin@nhs.net (general enquiries) or svyicb-doncaster.rxline@nhs.net (Clinical Enquiries)